Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 701–800 of 1,000
Direct factor Xa inhibitor edoxaban: from bench to clinical practice
Brekelmans, M. P. A., Middeldorp, S., & Coppens, M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1111756 · Cited by 4
Rudakova, A. V. (2015) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2015-11-5-496-503 · Cited by 4
Evans, N. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_5 · Cited by 3
Kroeger, K., Pleye, J., Pourhassan, S., Peter, J., & Noppeney, T. (2018) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-0612-8244 · Cited by 2
“[13] Schulman S, Kearon C, Kakkar AK et al.”
BackgroundCouturaud, F., Fischer, A., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.003 · Cited by 3
Fatigue after initiating rivaroxaban for venous thromboembolism
Karlsvik, T. M., Borgenvik, T. L., Aadalen, M., Utne, K. K., Førsund, E., Jørgensen, C. T., Holst, R., Jelsness‐Jørgensen, L., Ghanima, W., & Kahn, S. R. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12312 · Cited by 2
Treatment of Acute Venous Thromboembolism
Nair, S. N., Garza, N., George, M., & Kaatz, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.004 · Cited by 3
Wang, Z., Zhao, X., He, P., Chen, S., Jiang, J., Harada, A., Brooks, S., & Cui, Y. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01439-2 · Cited by 2
Camporese, G., Simioni, P., Micco, P. D., Fernández‐Capitán, C., Rivas, A., Font, C., Sahuquillo, J. C., Villares, P., Prandoni, P., Monréal, M., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12876 · Cited by 2
Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method
Janknegt, R., Metting, E., Kooistra, J., & Dekhuijzen, R. P. N. (2020) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2020.04.0640 · Cited by 2
Khan, F. A., Thavorn, K., Coyle, D., van Katwyk, S., Tritschler, T., Hutton, B., Gal, G. L., Rodger, M. A., & Fergusson, D. A. (2023) · BMJ Open · doi:10.1136/bmjopen-2021-053927 · Cited by 2
Malerba, P., Laera, N., Pagnesi, M., Bonzi, B., Rizzoni, D., Metra, M., & Nardin, M. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001551 · Cited by 2
Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review
Siniscalchi, C., Imbalzano, E., Meschi, T., Ticinesi, A., Prati, B., Basaglia, M., Camporese, G., Perrella, A., Viorica, A., Eletto, E., et al. (2024) · Medicina · doi:10.3390/medicina60081240 · Cited by 4
Li, Y., Xi, L., Wang, D., Fan, G., Li, X., Shi, Y., Chen, H., Deng, C., Chen, H., Luo, Q., et al. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109237 · Cited by 2
Devabhakthuni, S., Yoon, C. H., & Pincus, K. J. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190014568388 · Cited by 2
Kapur, V., & Goyal, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119467779.ch14 · Cited by 2
Derin Ven Trombozunda Güncel Tedaviler
Tekin, G. (2015) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.54870 · Cited by 3
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism
Ogbonna, K. C., & Dixon, D. L. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s54033 · Cited by 3
“Phase ii: extended treatment of vTe Extended treatment of VTE with dabigatran was studied in two separate trials, RE-MEDY and RE-SONATE.(29) RE-MEDY compared the noninferiority of dabigatran 150 mg twice daily vs dose-adjusted warfarin (INR: 2.”
InfluentialLes nouveaux anticoagulants oraux dans la maladie thromboembolique veineuse
Scarlatti, D., & Ferrari, É. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70532-7 · Cited by 2
Different Classes of Anticoagulant Drugs in Clinical Use. Is there a Class Effect?
Iqbal, O. (2015) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000197 · Cited by 2
“REMEDY [8] Randomised (Active Control study) 2856 Recurrent VTE Dabigatran at a dose of 150 mg twice daily vs warfarin Primary Efficacy outcome: Recurrent symptomatic and objectively verified VTE or death associated with VTE.”
BackgroundVenous thromboembolism: Diagnosis, treatment and the prevention of long-term complications
Barnes, G. D., Froehlich, J. B., Kanthi, Y. M., & Wakefield, T. W. (2014) · Reviews in vascular medicine · doi:10.1016/j.rvm.2014.07.005 · Cited by 2
Symons, G. (2014) · South African Medical Journal · doi:10.7196/samj.7873 · Cited by 4
“[11] Clinically, this characteristic allows renal-based dosing without routine monitoring, which is a significant advantage over the VKAs.”
BackgroundHajhosseiny, R., Sabir, I. N., & Lip, G. Y. H. (2014) · Hospital Practice · doi:10.3810/hp.2014.10.1152 · Cited by 2
Toth, P. P. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912833 · Cited by 3
“Major bleeding was not signifi cantly increased compared with placebo in EINSTEIN EXT, AMPLIFYEXT, or RE-SONATE and was similar to warfarin in RE-MEDY (Table VI) (20,23,59).”
BackgroundMethodResultMookadam, M., Shamoun, F., Ramakrishna, H., Obeid, H., Rife, R., & Mookadam, F. (2015) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.166461 · Cited by 2
“Dabigatran was also studied for the treatment of VTE in patients who were believed to be at increased risk of recurrent disease in the RE-MEDY and the extended use of dabigatran, warfarin, or placebo in VTE (RE-SONATE and RE-MEDY) Trial.[19] The RE-MEDY study design included patients who were already treated for Table…”
BackgroundHoly, E. W., & Beer, J. H. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.001 · Cited by 2
“In RE-SONATE dabigatran was compared to placebo in extended VTE therapy [6].”
MethodOral direct thrombin inhibition: a double-edged sword?
Fragasso, G., Corti, A., Loiacono, F., Margonato, A., & D’Angelo, A. (2015) · PubMed Central · Cited by 3
Venous Thromboembolism in the Elderly
Ali, M. S., & Czarnecka‐Kujawa, K. (2016) · Current Geriatrics Reports · doi:10.1007/s13670-016-0163-z · Cited by 2
Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism
Joseph, L., & Bartholomew, J. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416652236 · Cited by 2
Reversal of Dabigatran with Idarucizumab
Sodha, N. R., & Sellke, F. W. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1203253 · Cited by 2
“6% for those being treated for venous thromboembolic disease [5,6].”
BackgroundMeneveau, N. F. (2015) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2015.07.003 · Cited by 3
Overview of the Direct Oral Anticoagulants
Skeik, N., Sethi, A. R., & Shepherd, M. F. (2017) · Journal of the Minneapolis Heart Institute Foundation · doi:10.21925/mplsheartjournal-d-16-00005 · Cited by 2
2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants
Park, Y. M., Park, H. W., Lee, J., Park, J., Lee, K. H., Kim, J., Lee, Y. S., & Joung, B. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.1.57 · Cited by 2
“5 mg bid Dabigatran [184] 150 mg bid Edoxaban Not studied Rivaroxaban [185] 10 mg qd Deep vein thrombosis prophylaxis after orthopedic surgery Apixaban [186] 2.”
Shakerian, F., & Sadeghipour, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-51149-0.00029-8 · Cited by 2
Akute Beinvenenthrombose – moderne Diagnostik und Therapie
Thrombose-Initiative e., V., Kröger, K., & Moerchel, C. (2019) · Gefässchirurgie · doi:10.1007/s00772-019-0531-z · Cited by 3
Drug-Induced Disorders and Dental Implant Treatment
Hsiao, C. Y., & Qing, H. (2019) · Springer eBooks · doi:10.1007/978-3-030-28557-9_8 · Cited by 2
Kozák, P., Xu, M. J., Farber‐Eger, E. H., Gailani, D., Wells, Q. S., & Beckman, J. A. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013395 · Cited by 2
Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban
Choo, A., Bragagnolo, A., Ekanayake, S., & Alghamry, A. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2585 · Cited by 2
The use of new oral anticoagulants in geriatric patients: A survey study for physicians
Duru, S. A., Bahadır, A., & Ertürk, A. (2021) · Tuberkuloz ve Toraks · doi:10.5578/tt.20219908 · Cited by 2
“Previous prospective, randomized and placebo-controlled studies have reported NOACs to be as effective as warfarin and low-molecular-weight heparins (LMWHs) in terms of recurrence and early mortality in patients with deep vein thrombosis (DVT) and stable pulmonary thromboembolism (PTE), and report that they are associ…”
BackgroundXu, K., Chan, N., & Eikelboom, J. W. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1965124 · Cited by 2
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_18 · Cited by 4
Maladie thromboembolique veineuse
Monsuez, J. J. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70489-9 · Cited by 2
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients
Ravikumar, R., Lim, C. S., & Davies, A. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_31 · Cited by 2
Benito, L., Lobato, C. T., & Martín, E. V. (2023) · FarmaJournal · doi:10.14201/fj2023813347 · Cited by 2
Dağtekin, E., & Çelik, S. (2023) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2023.2023-3-8 · Cited by 2
Shakerian, F., Sadeghipour, P., & Talasaz, A. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00029-6 · Cited by 2
More indications approved and safety news for dabigatran etexilate.
Cintezǎ, M. (2014) · Europe PMC (PubMed Central) · Cited by 1
Reardon, D. P., & Zemaitis, C. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-71240-6_10 · Cited by 1
Mühlbauer, B., & Wille, H. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_9 · Cited by 1
Albukhari, A. F., AlHarbi, Y., Alqahtani, M. M., Hageen, A. W., Ibrahim, A. A., Alhomidani, F., Alshammari, T. G., Albalawi, T., Alshehri, S., Alayidh, M. A., et al. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2554467 · Cited by 3
“18,27 Consistent with this, prior investigations by Schulman et al 28 and Franco et al 29 have established that prolonged, lower-intensity anticoagulation may contribute to durable secondary prevention of VTE, particularly in patients at elevated bleeding risk.”
Safety and optimal use of direct oral anticoagulant therapy
Laudani, C., Ortega‐Paz, L., Zgheib, A., Khoury, G. E., Alawajneh, M. M., Farahmandsadr, M., Capodanno, D., & Angiolillo, D. J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586121 · Cited by 2
“In the RE-SONATE trial, patients with VTE who completed 3-month anticoagulation were randomized to receive dabigatran 150 mg or placebo [51].”
Deng, D., Xu, Z., & Zhu, W. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251408061 · Cited by 1
Jeong, J., Ah, Y., Han, J. M., Min, S., Shin, J., Heo, K., & Lee, J. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.018 · Cited by 2
Ali, M. F., Naseer, F., Hageen, A. W., Hayat, S., Rashid, Z., Momna, F. N. U., Sawaira, F., Riaz, A. A., Ahmad, H. F., Eltawansy, S., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70142 · Cited by 1
Chen, J., Chen, Q., Guan, C., & Xia, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1835091 · Cited by 1
Páramo, J. A., Alfonso, A., & Lecumberri, R. (2014) · Angiología · doi:10.1016/j.angio.2014.07.021 · Cited by 3
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Tromeur, C., & Couturaud, F. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.07.005 · Cited by 1
“Enfin, dans l'étude RE-MEDY, le Dabigatran (150 mg deux fois par jour) était comparé à la warfarine pendant 18 mois médians [68] : aucune différence significative n'a été observée entre les deux bras en termes de récidive ou d'hémorragie ; toutefois, sous dabigatran, la fréquence d'une infarctus en cours d'étude était…”
BackgroundPractical recommendations on incorporating new oral anticoagulants into routine practice.
Randhawa, J. S., Thiruchelvam, N., Ghobrial, M., Spiro, T. P., Clark, B. A., Haddad, A. S., & Daw, H. A. (2014) · PubMed · Cited by 1
Blickstein, D., Eliakim‐Raz, N., & Gafter‐Gvili, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088 · Cited by 1
Komplikationen und Spätfolgen von Thrombosen
Dellas, C., Konstantinides, S., Blättler, W., Gerlach, H.-E., & Salzmann, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-21496-7_14 · Cited by 1
Tromboembolia pulmonar: revisión sistemática y algoritmo diagnóstico-terapéutico
Gorordo-Delsol, L. A., Zamora-Gómez, S. E., Hernández-López, G. D., García-Román, M. T. A., Jiménez-Ruiz, A., & Tercero-Guevara, B. I. (2015) · Revista del Hospital Juárez de México · Cited by 1
Target-specific oral anticoagulants and the hospitalist
Deitelzweig, S. B., & Amin, A. (2015) · Hospital Practice · doi:10.1080/21548331.2015.998157 · Cited by 1
Switching between Oral Anticoagulants
Strasser, K. M., Qasem, A., & Madhusudhana, S. (2014) · Hospital Practice · doi:10.3810/hp.2014.08.1119 · Cited by 1
Long-term dabigatran therapy reduces the risk of recurrent venous thromboembolism
Cully, M. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.33 · Cited by 1
Paje, D. G., & Kaatz, S. (2013) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2013.04.004 · Cited by 2
Maladie thromboembolique veineuse
Monsuez, J.-J. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70512-1 · Cited by 1
Jiménez, D., Kopecna, D., de Miguel‐Díez, J., & Sueiro, A. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70882-0 · Cited by 2
Highlights of the American Society of Hematology Meeting 2013: hemostaseology
Feistritzer, C., & Wildner, S. M. (2014) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-014-0157-5 · Cited by 1
“The authors analyzed already published large prospective, multi-center trials [9–12].”
BackgroundSafety and Efficacy of Target-Specific Anticoagulants in Patients With Venous Thromboembolism
Lekura, J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014568550 · Cited by 1
Palareti, G. (2014) · Veins and Lymphatics · doi:10.4081/vl.2014.4148 · Cited by 1
New oral anticoagulants: their role and future
Shapiro, S., & Laffan, M. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-6-s53 · Cited by 1
Robinson, M. (2015) · Open Journal of Nursing · doi:10.4236/ojn.2015.512121 · Cited by 1
“Data from large phase III trials investigating the efficacy and safety of the non-VKA OACs in the long-term secondary prevention of VTE showed that these agents exhibited a superior efficacy compared with placebo, without significantly increasing the risk of major bleeding [34] [40] [41].”
BackgroundLungenembolie auf der Intensivstation
Dürschmied, D., Heinz, J., Siepe, M., & Bode, C. (2015) · Intensivmedizin up2date · doi:10.1055/s-0034-1391389 · Cited by 1
Fonyakin, A. V., & Гераскина, Л. А. (2013) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2013-2448 · Cited by 1
Anticoagulation Treatment Using NOAC in Patients with Venous Thromboembolism
Yoon, N. (2016) · International Journal of Arrhythmia · doi:10.18501/arrhythmia.2016.005 · Cited by 1
Simplifying and interpreting the FACTS of noninferiority trials: A stepwise approach
Thornby, K., Johnson, A., & Ferrill, M. J. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130270 · Cited by 1
Intraperitoneal Hemorrhage in a Peritoneal Dialysis Patient Using Dabigatran: A Case Report
Cebeci, E., Samancı, N. Ş., Gürsu, M., Şumnu, A., Karadağ, S., Uzun, S., Tatlı, E., Behlül, A., Koç, L., Aydın, Z., et al. (2016) · Medical Bulletin of Haseki · doi:10.4274/haseki.2922 · Cited by 1
Es lohnt sich heute, länger zu antikoagulieren! Venöse Thromboembolie
Einecke, D. (2013) · CME · doi:10.1007/s11298-013-0957-7 · Cited by 1
The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_108 · Cited by 1
The Direct Oral Anticoagulants
Garcia, D. A., Crowther, M. A., & Ageno, W. (2016) · Wiley eBooks · doi:10.1002/9781118344729.ch18 · Cited by 1
New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
Jang, S.-W. (2016) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2016.16.4.178 · Cited by 1
“심방세동과 정맥혈전증에 대한 3상 연구를 Table 2에 요약하 였다.(3-6,13-35)”
The management of venous thromboembolism: A practical tool for the front-line clinician
Bungard, T. J., & Semchuk, W. (2017) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163517691062 · Cited by 1
“Notably, the only dose of dabigatran studied in VTE is the 150 mg twice-daily dosing.(23,24,34) Despite this, the product monograph suggests applying the lower 110 mg twice-daily dose for those patients fulfilling criteria for this dose for the indication of atrial fibrillation.”
Weiss, T. W., Rohla, M., Dieplinger, B., Domanovits, H., Fries, D. R., Voško, M. R., Gary, T., & Ay, C. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-017-0548-4 · Cited by 1
Therapie und Sekundärprävention der venösen Thromboembolie – Orale Antikoagulation im Wandel
Helms, T., Gulba, D. C., Ahrens, I., Schäfer, A., Hankowitz, J., Kuhlencordt, P., Lipp, H., Nikol, S., Riess, H. B., Stargardt, T., et al. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-124132 · Cited by 1
Anticoagulación extendida en la enfermedad tromboembólica venosa. A favor
Capitán, M. C. F. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.02.017 · Cited by 1
NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOSIS
Laguta, P. S. (2016) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2016-1-5-15 · Cited by 1
Extended anticoagulation in venous thromboembolism disease. In favor
Fernández, M. C. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.04.003 · Cited by 1
Case of acute pulmonary embolism in post pneumonectomy-a rare clinical presentation and management
Manjunath, B. V., Sahoo, B. C., Thakre, G. P., & Gudage, N. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20173599 · Cited by 1
“The other most important thing regarding the management is initiating LMWH and dabigatran (NOAC) to prevent pulmonary infarction of the normal lung considering our patient has undergone right pneumonectomy in the past.(4-6) The duration of”
BackgroundQuel traitement anticoagulant au décours d’une embolie pulmonaire
Mao, R. L., Tromeur, C., & Couturaud, F. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.06.015 · Cited by 1
Direct-acting oral anticoagulants: An overview
Salem, H. (2017) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_83_17 · Cited by 2
“Dabigatran in the extended treatment of venous thromboembolism Two studies (RE-MEDY and RE-SONATE) examined the efficacy of dabigatran in extended treatment.[22,23] All patients completed 3–6 months of their venous thrombosis treatment before being eligible for enrolment in the extended treatment studies.”
BackgroundSlovenska priporočila za odkrivanje in zdravljenje venske tromboze
Kozak, M., Štalc, M., Jezovnik, M. K., Šabović, M., Mavri, A., Žuran, I., Blinc, A., & Cuderman, T. V. (2016) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1481 · Cited by 4
Anticoagulation for Proximal Deep Vein Thrombosis
Lee, A. I., & Lee, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-65226-9_23 · Cited by 1
Abdel‐Razeq, H., Finianos, A. N., & Taher, A. T. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1480363 · Cited by 1
“VTE treatment in RE-COVER [17], RE-COVER II [18], RE-MEDY [19], and RE-SONATE [20] trials.”
Lawall, H. (2018) · Gefässchirurgie · doi:10.1007/s00772-018-0402-z · Cited by 1
Romero, J. M. C., & Rodríguez, E. M. L. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2018.05.004 · Cited by 1
Zawilska, K. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0009 · Cited by 1
Anticoagulants and Treatment of Venous Thromboembolism
Burnett, A., & Ansell, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-97873-4_17 · Cited by 1
A MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. PART II
Shalnev, V. I. (2018) · EMERGENCY MEDICAL CARE · doi:10.24884/2072-6716-2017-18-4-60-65 · Cited by 1
New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report
Arcadi, F. A., Portaro, S., Giorgianni, R., Naro, A., Casella, C., Genovese, C., Marino, S., & Calabrò, R. S. (2019) · Medicina · doi:10.3390/medicina55030071 · Cited by 1
“In these interesting studies, it has been demonstrated that dabigatran had similar effects on VTE recurrence and a lower risk of bleeding when compared to warfarin [16,17].”
BackgroundMacGillivray, T. E. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.01.049 · Cited by 1
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.